What Zepbound®, Wegovy®, Mounjaro® and Ozempic® actually are, how they work and how they differ. For education only. Talk to your clinician before changing anything.
Zepbound®, Wegovy®, Mounjaro®, and Ozempic® are FDA-approved injectable pens. Their published results - SURMOUNT-1 and STEP-1 in NEJM - apply to these branded products specifically. At PinwellRx, a licensed clinician evaluates you online and, when appropriate, prescribes; your pen ships from a licensed U.S. pharmacy.
The brand name for tirzepatide from Eli Lilly, supplied as a once-weekly injection. It is FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and increased physical activity, and separately for moderate-to-severe obstructive sleep apnea in adults with obesity.
Tirzepatide activates two gut-hormone receptors, GIP and GLP-1. Together they slow how quickly the stomach empties and signal fullness to the brain, which is why appetite feels quieter between meals. It works with the same signalling system your body already uses after eating.
Same active molecule, tirzepatide, from the same manufacturer, but they are separate products with separate FDA-approved uses. Zepbound® is approved for weight management and sleep apnea; Mounjaro® is approved for type 2 diabetes. Your clinician prescribes according to what you are being treated for.
Once a week, on the same day each week, at any time of day, with or without food. The label directs injecting under the skin of the abdomen, thigh or upper arm, rotating the site each week. Your clinician and the Instructions for Use walk you through it before your first dose.
Yes, store it in the refrigerator per the label. Pens may be kept at room temperature for a limited number of days if needed, as specified in the FDA labeling, and should not be frozen or used after that window. Follow the storage instructions dispensed with your medication.
Nausea, diarrhoea, vomiting, constipation, stomach pain, indigestion and fatigue are the commonly reported effects, and they most often appear in the days following a dose increase. Dose steps are deliberately gradual for that reason. Anything severe or persistent is a reason to message your care team rather than wait it out.
Hair thinning is not an established adverse reaction in the FDA labeling. Temporary shedding can follow rapid weight loss of any cause, including from diet alone, and usually settles. If you notice it, raise it with your clinician so nutrition and other causes can be reviewed.
Self-pay pricing depends on dose and pharmacy, and it is set by the manufacturer and participating pharmacies rather than by a telehealth platform. Lilly operates a self-pay channel and a commercial savings card, both worth checking directly. PinwellRx does not dispense brand products and does not accept insurance. There is a boxed warning for thyroid C-cell tumours; a clinician reviews it with you.
The brand name for semaglutide from Novo Nordisk, supplied as a once-weekly injection and FDA-approved for chronic weight management in eligible adults and adolescents, alongside diet and increased physical activity. It also carries an approved indication for reducing cardiovascular risk in certain adults.
Both contain semaglutide from the same manufacturer, but they are separate products approved for different uses at different dose ranges. Wegovy® is approved for weight management; Ozempic® is approved for type 2 diabetes. They are not interchangeable, and only your clinician decides which is appropriate.
One injection a week, on the same day each week, at any time of day, with or without food, under the skin of the abdomen, thigh or upper arm. Doses are stepped up gradually over several weeks to help with tolerability.
Yes. Wegovy® Tablets are an FDA-approved once-daily oral form of semaglutide. The timing rules are different from the pen: the label directs taking it on an empty stomach with a small sip of plain water, then waiting before anything else. We have a separate answer library for the tablets.
Nausea, diarrhoea, vomiting, constipation, stomach pain, headache and fatigue are the commonly reported effects across this class, most often after a dose increase. Semaglutide carries a boxed warning for thyroid C-cell tumours, and your clinician reviews your history and the full labeling with you.
They are approved for type 2 diabetes, not for weight management. Mounjaro® is tirzepatide and Ozempic® is semaglutide; Ozempic® also carries an approved indication for cardiovascular risk reduction in certain adults with type 2 diabetes. Prescribing either for weight is an off-label decision only a licensed clinician can make.
Sometimes it comes down to what you are being treated for, your medical history, or what a pharmacy can actually supply. That judgement belongs to the clinician who reviews your intake, and they may conclude that a different medication, or none, is the right answer.
They are the same molecule approved at different dose ranges for different conditions, so “stronger” is the wrong frame. Comparing them is a clinical conversation about indication and dose, not a ranking.
No. PinwellRx does not dispense brand products. Zepbound®, Wegovy®, Mounjaro® and Ozempic® are supplied through their manufacturers and retail pharmacies, and a prescriber outside this platform would write for them. What PinwellRx offers is compounded preparations, which are not FDA-approved and are not equivalents of these products. This page exists so you can understand the difference before deciding what to ask a clinician about.
Every therapy we offer has its own answer library, same format, same honesty. Films for the tablets are in production.
A licensed clinician reviews every intake. You’ll see your price before you pay, and nothing ships unless a clinician prescribes it.